Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Sun Pharma Advanced Research Company Limited

SPARC · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹176.46

−₹6.52 (−3.56%)(1D)

₹108.0052 Week Range₹289.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

70/100

Valuation

94/100

Quality

59/100

Growth

100/100

Health

44/100

Momentum

45/100

Valuation
94
Quality
59
Growth
100
Health
44
Momentum
45

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Sun Pharma Advanced Research Company Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹176.46

Market cap

₹5,725 Cr

P/E ratio

3.61

P/B ratio

4.28

Dividend yield

Not available

ROE

Not available

RSI 14

39.09

1Y return

Sun Pharma Advanced Research Company Limited FAQs

3 topics

ExpandCollapse

Not available

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Sun Pharma Advanced Research Company Limited (SPARC) stock page cover?

Sun Pharma Advanced Research Company Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for SPARC?

Sun Pharma Advanced Research Company Limited is currently shown with a delayed price near ₹176.46, P/E 3.61.

Does the SPARC page provide investment advice?

No. The SPARC page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

INNOVACAP

Innova Captab Limited · Healthcare

FDC

FDC Limited · Healthcare

MOREPENLAB

Morepen Laboratories Limited · Healthcare

How to Use Anvest Intelligence Effectively: 10 Practical AI Stock Research Prompts

Master AI-assisted stock research on Indian equities. Learn how to construct grounded financial queries, audit concall guidance, verify filing citations, and avoid ungrounded AI hallucinations.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Sun Pharma Advanced Research Company Limited (SPARC) is an India-based pharmaceutical company focused on innovative research and development of new drug delivery systems and novel chemical entities. It operates primarily in the R&D space, aiming to create differentiated products for global markets, leveraging its association with the larger Sun Pharma group.

Drug Manufacturers - Specialty & GenericFounded:2007CEO/MD:Anil Kumar GuptaHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

The entity has three national locations, including R&D facilities, and one international office.
SPARC primarily generates revenue through research and development activities, including licensing out its intellectual property, receiving milestone payments, and potentially commercializing its own advanced drug formulations.

What Looks Strong

ValuationTrailing P/E is 3.7×. The valuation score is 94/100.

What to Watch

RevenueRevenue declined about 5% in FY25 (consolidated: ₹75.5 cr → ₹71.8 cr). Watch whether the next results confirm a trend or a one-off.
MarketShares have lagged the Nifty 500 by 16.7 percentage points annualized over three years.

Reports a single operating segment in its results filings.
Its core focus is on creating value through innovation in drug development.
SPARC's operations are centered around Scientific Research and Development, representing 100% of its turnover.

FY25 (consolidated): revenue ₹71.8 cr, down 5% from ₹75.5 cr in FY24; the net loss narrowed to ₹343 cr from ₹387 cr in FY24.
FY25 (consolidated): operating cash flow −₹360 cr; debt/equity 0.42×.
Latest quarter to Jun 2026 (consolidated): revenue ₹39.9 cr (4.1× a year earlier); a net loss of ₹20.8 cr.